Loading
companiesCompany
Clovis Oncology
Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023.
Also called: Clovis Oncology, Inc.
Overview
Clovis Oncology, based in Boulder, Colorado and listed on Nasdaq, developed rucaparib (Rubraca), a PARP inhibitor approved in the United States from 2016 for BRCA-mutated ovarian cancer, then as maintenance therapy (ARIEL3) and for BRCA-mutated metastatic castration-resistant prostate cancer (TRITON2). An earlier lead, the EGFR inhibitor rociletinib, was abandoned in 2016 after disputed response data. Competition from other PARP inhibitors and a restricted label left the company unable to service its debt; it filed for Chapter 11 in December 2022 and sold Rubraca to pharma& in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Boulder, CO, US
Scorecard
All companies#178of 1244 companies, score 32
- approved products +6
- targets +4
- modalities +2
- regions +4
- 24-month regulatory events +2
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 2 targets, 49 registry studies. Formula on the scorecards page.
Type
Stage
Wound down
Website
ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca
A PARP inhibitor for BRCA-mutated ovarian and prostate cancer whose original maker went bankrupt; still available, with a narrowed label.
rctNew England Journal of Medicine 2023changed practice374 citations
TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer
The randomised proof for PARP inhibition in BRCA-altered prostate cancer, and the clearest evidence that the homologous recombination repair gene list should not be used as a single yes-or-no test. ATM-altered disease needs a different answer, and does not yet have one.
rctJournal of Clinical Oncology 2020changed practice561 citations
TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration
The trial behind the second PARP inhibitor licensed in prostate cancer, and the evidence that a somatic BRCA alteration predicts response as well as an inherited one. Together with TOPARP-A it is why tumour as well as germline sequencing is recommended in metastatic disease.
Similar pages
- TermWho is eligible for a PARP inhibitor in prostate cancer, and why the gene matters
Shares TRITON3, Rucaparib, PARP, Prostate cancer.
- Key paperPROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations
Shares TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer, TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration, PARP, Prostate cancer.
- PersonRuth Plummer
- TermGenome-wide loss of heterozygosity (gLOH)
Shares TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer, TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration, Rucaparib, Prostate cancer.
- Key paperTalazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Shares TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialPROfound
Shares TRITON3, PARP, Prostate cancer.
- PersonBradley J. Monk
Shares ATHENA-MONO / GOG-3020, Ovarian cancer.
- TechnologyRAD51 foci assay (functional HRD test)
Shares Rucaparib, PARP, Ovarian cancer, Prostate cancer.
cancers
fronts
targets
drugs
ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca